The exciting discovery that BRD4780 targets pathological TMED9-MUC1 aggregates to lysosomes demonstrates the potential to pharmacologically target TMED proteins for the resolution of proteinopathies (Dvela-Levitt et al., 2019). Here, MUC1 is linked to proteostasis deficiencies.